My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.75 +0.03 (+0.06%)
Streaming Delayed Price Updated: 3:49 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 Next >
This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday
 
Via Benzinga
Unusual volume stocks in Thursday's session
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud... 
Via Chartmill
Topics Economy
Let's take a look at the stocks that are in motion in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
Via Stocktwits
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Novartis agreed to buy a cardiovascular-focused biotech company 
Via Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company. 
Via Investor's Business Daily
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Nebius Group Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Tourmaline Bio Reports Loss as R&D Rises
Via The Motley Fool
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
What's going on in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
 
Via Benzinga
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. 
Via Benzinga
Topics Stocks
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.